
Sponsored
Matt Whelihan, associate director of research and development at Prolytix, discusses industry trends—from data-driven approaches built on artificial intelligence (AI) to increasingly complex therapeutic modalities.

Sponsored
Matt Whelihan, associate director of research and development at Prolytix, discusses industry trends—from data-driven approaches built on artificial intelligence (AI) to increasingly complex therapeutic modalities.

Sponsored
Mike Riley, CEO of Veranova, discusses how people-first leadership, deep experience in complex chemistries, and close collaboration with customers position the CDMO to support increasingly complex modalities.

Sponsored
Sandra Reid, senior director of sales at gChem, shares what scientists should be asking before choosing a sterile DMSO for their next cell therapy or parenteral program.

Sponsored
Christine Fuerst and Gregor Deutschle of Vetter Pharma International GmbH discuss what pharmaceutical and biotech companies expect from a fill and finish CDMO partner today.

Sponsored
Peter Schmidt, PhD, breaks down a major shift in FDA thinking that's changing how sponsors plan their earliest trials.

Webcasts
Webinar Date/Time: Fri, Sep 25, 2026 11:00 AM EDT

Sponsored
Success in emerging biopharma depends not only on speed, but also on making confident, data-informed decisions early in development while managing increasing molecular complexity.

Sponsored
Discover how a new mid-scale DynaDrive™ bioreactor platform and KojoX™ philosophy are redefining supply-chain security and manufacturing consistency across a growing global network.

Sponsored
Ajay Damani, President of Coating Place, discusses the impact of the current CDMO landscape on oral solid dose pharmaceuticals.

Sponsored
The evolution of Pace® Life Sciences from an analytical services firm to a full-service CDMO supporting the drug development lifecycle.

Sponsored
Discover how Piramal Pharma Solutions is innovating in integrated CDMO services, leveraging their Science Collective of experts to streamline drug substance and drug product programs from early development through commercialization.

Sponsored
Emily Schirmer, Catalent, explains how to accelerate the path to first-in-human trials as biologics pipelines grow more complex and timelines tighten.

Sponsored
Christian Houborg discusses how FUJIFILM Biotechnologies is helping customers navigate evolving patient demand and supply chain uncertainty.

Sponsored
The CDMO landscape is shifting toward long-term strategic partnerships as drug modalities grow more complex and supply chain pressures mount. Noritsugu Fujita, Division President of Pharmaceutical Solutions Division at Terumo, explains how an integrated, single-source model for parenteral drug development aims to streamline the path to a patient-ready product.

Sponsored
Peter Belden, Tjoapack, discusses how the rise of specialized medicines for smaller patient populations is necessitating more flexible, redundant packaging capacity to manage complex global distribution requirements.

Sponsored
Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges.

Sponsored
Joerg Ahlgrimm, CEO of SK pharmteco, outlines the company's strategic expansion into cell and gene therapy. He also details their commitment to global operational excellence and a culture of employee purpose.

Sponsored
Fernanda Onofre, PhD, explains how the dsm-firmenich ModulaSENSE® Bitter platform and the functional application of vitamins as excipients are revolutionizing drug palatability and performance.

Sponsored
Terry Novak, CEO of Benuvia, explores how pharmaceutical and biotech companies can mitigate development risks and accelerate speed-to-market by prioritizing technical alignment, robust project management, and early-stage collaboration with the right CDMO partner.

Sponsored
Hear from Miguel Ángel Ortega Sánchez, Corporate Industrial Director at ROIS CDMO, as he breaks down the company’s new brand, a strategic acquisition, and what these moves mean for ROIS’s future as a global leader in high-value injectables.

Sponsored
LabVantage is advancing software as a service (SaaS) for the laboratory information management system (LIMS) market to provide laboratories with reduced costs and pre-validated solutions that facilitate scalability and faster speed-to-market for pharmaceuticals

Sponsored
Nina Moreno, Nelson Labs, explains how rapid sterility testing is reshaping pharmaceutical quality control—cutting release times, improving objectivity, and gaining regulatory momentum.

Sponsored
Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small molecule APIs to advance biocatalysis across pharma.

Sponsored
Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.

Sponsored
A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Sponsored
Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.

Sponsored
Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.

Sponsored
The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand from attendees about challenges and insights from the front lines of amorphous drug development.

Sponsored
Watch this interview and learn how advances in patient-centric drug delivery are transforming ten23 health's development strategies as a next-generation CDMO.
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
Sponsored
In this interview, Sandra Reid of gChem explains how PROCIPIENT®, its USP-grade DMSO, is uniquely manufactured under cGMP and ICH Q7 guidelines to ensure compliance, consistency, and quality across global pharmaceutical markets.